Skip to main content
Landing Pages / Faculty Profile
Photo of  James J. Driscoll, MD, PhD

James J. Driscoll, MD, PhD

Assistant Professor of Medicine

  • Fellowship: Dana-Farber Cancer Institute (Oncology)
  • Residency: Roger Williams Medical Center
  • Medical Degree: St. Mary's School of Medicine
  • Research Fellow: Boston University Medical Center
  • Research Fellow: Harvard Medical School
  • Doctoral Degree: State University of New York at Buffalo (Biochemistry)
Contact Information
Research Interests

Proteasome-based therapies, plasma cell hematologic malignancy, Multiple Myeloma, Hematology Oncology

Peer Reviewed Publications

Ahmad, N; Haider, S; Jagannathan, S; Anaissie, E; Driscoll, J J 2014. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia, 28 4, 732-8

Haider, Sajjad; Ahmad, Nisar; Anaissie, Elias; Driscoll, James J 2014. Future directions in the clinical management of amyloid light-chain amyloidosis. Leukemia & lymphoma, ,

Driscoll, JJ, Amin, S., Le Pape, E., Lee, MJ, Trepel, J., Tannous, BA, Munshi, NC, Anderson, KC and Annunziata, CM. 2013. Cullin-1 controls the clinical and cellular response to bortezomib through NF-B pathway activation in myeloma , ,

Driscoll, JJ, Khaled, A, Jagannathan, S. and Subramani, A. 2013. The Mammalian Target of Rapamycin as a Therapeutic Strategy in Oncology in Mammalian Target of Rapamycin (mTOR): Structure, Signalling Pathways and Biological Effects , ,

Driscoll, JJ, Khaled, A, Jagannathan, S. and Subramani, A. 2013. Targeting the PTEN Tumor Suppressor as an Anti-Cancer Therapeutic Strategy. In PTEN: Structure, Mechanisms-of-Action, Role in Cell Signaling and Regulation , ,

Kim, Kui-Jin; Godarova, Alzbeta; Seedle, Kari; Kim, Min-Ho; Ince, Tan A; Wells, Susanne I; Driscoll, James J; Godar, Samuel 2013. Rb Suppresses Collective Invasion, Circulation and Metastasis of Breast Cancer Cells in CD44-Dependent Manner. PloS one, 8 12, e80590

Potluri, Veena; Noothi, Sunil K; Vallabhapurapu, Subrahmanya D; Yoon, Sang-Oh; Driscoll, James J; Lawrie, Charles H; Vallabhapurapu, Sivakumar 2013. Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. PloS one, 8 7, e66121

Subramani, A., Alsidawi, A., Jagannathan S., Sumita, K., Sasaki, AT, Aronow, B., Warnick, RE, Lawler, S. and Driscoll, JJ. 2013. Brain microenvironment-induced reduction in microRNA-768-3p promotes metastatic tumor growth, drug resistance and KRAS expression. , ,

Subramani, Arasukumar; Alsidawi, Samer; Jagannathan, Sajjeev; Sumita, Kazutaka; Sasaki, Atsuo T; Aronow, Bruce; Warnick, Ronald E; Lawler, Sean; Driscoll, James J 2013. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. Scientific reports, 3 , 2392

Driscoll J. and Woodle, E. Steve 2012. Targeting the ubiquitin+proteasome system in solid tumors, Seminars in Hematology, ,

Driscoll, J. and De Chowdhury, R. 2012. Targeted inhibition of the proteasome, aggresomes and autophagy as an anti-cancer strategy to enhance apoptosis and reduce drug resistance Cancer Letters, ,

Driscoll, J., Amin, S., Pelluru, D., Le Pape, E., Burris, J., Gootenberg, J., Li, C., Anderson, K.C., Lee, M-J., Trepel, J., Nie, M., Boddy, M.N., Munshi, N.C., and Annuniziata, C.M. 2012. Regulation of the clinical and cellular response to bortezomib in myeloma through he Skp1-Cullin1-Fbox E3 ubiquitin ligase complex Blood, ,

Driscoll, James J; Chowdhury, Roopa De 2012. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications. Cancer letters, 325 2, 147-54

Driscoll, James J; Woodle, E Steve 2012. Targeting the ubiquitin+proteasome system in solid tumors. Seminars in hematology, 49 3, 277-83

Driscoll, JJ., De Chowdhury, R. 2012. Molecular Crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications Cancer Letters, 325 , 147-154

Driscoll J., 2011. The SUMOylation pathway as a potential therapeutic target in Multiple Myeloma Multiple Myeloma, , 129

Driscoll J., Burris, J. and Annunziata, C.M. 2011. Targeting the Proteasome with Bortezomib in Multiple Myeloma: Update on therapeutic benefit as an upfront single agent, induction regimen for stem cell transplantation and as maintenance therapy American Journal Therapeutics, ,

Driscoll, J., Minter, A., Driscoll, D. an Burris, J. 2011. The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies Anti-Cancer Agents in Medicinal Therapy, Feb 11 , 242

Driscoll, J. and Rixe, O. 2010. In Cancer: Principles & Practice of Oncology Advances in Oncology, 1 ,

Driscoll, J. Pelluru, D., Lefkimmiatis, K., Fulciniti, M., Prabhala, R.H., Greipp, P., Barlogie, Tai, Y., Anderson, K.C., Annunziata C.M. and Munshi, N.C. 2010. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome Blood, 115 , 2827

Driscoll, J., and DeChowdhury, R. 2010. Therapeutically Targeting the SUMOylation, Ubiquitination and Proteasome Pathways as a Novel Anticancer Strategy Targeted Oncology, 5 , 281

Driscoll, J., Burris, J. and Annunziata, C.M. 2010. Novel Strategies in the Treatment of Mutiple Myeloma: From Proteasome Inhibitors to Immunotherapy Journal Cell Science, 1 , 101

Driscoll, J., De Chowdhury, R., Burris, J. and Annunziata, C.M. 2010. The Expanding Role of Proteasome-Based Therapy in the Treatment of Hematologic Malignancies Open Journal Hematology, 1 , 1

Gauerke, S. and Driscoll, JJ. 2010. Hidradenocarcinomas: A Brief Review and Future Directions Arch. Pathol. Lab Med., 134 , 781-785

Driscoll, J. and Rixe, O. 2009. Overall Survival - Still the Gold Standard The Cancer Journal, 15 , 401

Arnold, D., Driscoll, J. Androlewicz, M., Huges, El, Cresswell, P. and Spies, T. . Proteasome Subunits Encoded in the MHC are Not Generally Required for the Processing of Peptides Bound by MHC Class I Molecules Nature (London), 360 , 171

Brown, M., Driscoll, J. and Monaco, J.J. . MHC-Linked LMP and Proteasome Complexes are Not Identical: Implications for Divergent Function among Immunospecific Forms of the Proteasome Journal Immunology, 151 , 1193

Brown, M., Driscoll, J. and Monaco, J.J. . Structural and Seroloical Similarity of the MHC-Linked LMP and the Proteasome (Multicatalytic Protease) Complexes Nature (London), 353 , 355

Driscoll, J. and Finley, D.J. . A Controlled Breakdown: Antigen Processing and Turnover of Viral Proteins Cell, 68 , 823

Driscoll, J., Brown, M., Finley, D.J. and Monaco, J.J. . MHC-Linked LMP Gene Products Specifically Alter the Peptidase Activities of the Proteasome Nature (London), 365 , 262

Driscoll, JJ, and Goldberg, AL . Skeletal Muscle Proteasome can Degrade Proteins in an ATP-Dependent Process that does Not Require Ubiquitin Proc. Natl. Acad. Sci. U.S.A., 86 , 787-791

Driscoll, JJ., Goldberg, AL. . The Proteasome (Multicatalytic Protease) is a Component of the 1,500-kDa Proteolytic Complex which Degrades Ubiquitin-Conjugated Proteins J. Biol. Chem., 265 , 4789-4792